BHRT FOR MEN

Testosterone can be compounded in different strengths and dosage forms to meet your patient’s individual needs.  We can also compound with DHEA, Anastrozole, and Chrysin as well as other combinations for men.  Hormones can be compounded as oral tablets, sublingual tablets, or creams, as well as other dosage forms.  We can combine multiple hormones in one dosage form.  Belmar can provide you with prescribing templates to ease the writing of compounded hormone prescriptions.
 
Testosterone USP is bio-identical testosterone that has been approved by the United States Pharmacopoeia and is available as a bulk powder.  The testosterone comes from natural sources and then is purified by a major pharmaceutical company into the bio-identical form.  The term "Bio-Identical” means that the testosterone has the same molecular structure as the testosterone made in the human body and is chemically and functionally the same.  Testosterone is a scheduled III controlled substance.
 
 
 

Research

Loria, K. (2016). Polycythemia risk evaluated in patients on TRT pellets. Urology Times. [online] Available at: http://urologytimes.modernmedicine.com/urology-times/news/polycythemia-risk-evaluated-patients-trt-pellets?page=0,1.

Schwartz, E., Holtorf, K. and Brownstein, D. (2009). The Truth About Hormone Therapy .Printed inThe Wall Street Journal, p.A17.
 
Morley, J. (2009). The benefits and risks of testosterone replacement therapy: a review.  Therapeutics and Clinical Risk Management, 5, pp.427-448.
 
 
 Metabolic Syndrome

 
Kelly, D. and Jones, T. (2013). Testosterone: a metabolic hormone in health and disease. Journal of Endocrinology, 217(3), pp.R25-R45.
 
Muraleedharan, V. and Hugh Jones, T. (2010). Testosterone and the metabolic syndrome.  Ther Adv Endocrinol Metab, 1(5), pp.207–223.

Diabetes


Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. and Jones, T. (2013). Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169(6), pp.725-733. 

 
Mortality
 
Sharma, R., Oni, O., Gupta, K., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V., Ambrose, J. and Barua, R. (2015). Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J, 36(40), pp.2706-2715.
 
Shores, M., Smith, N., Forsberg, C., Anawalt, B. and Matsumoto, A. (2012). Testosterone Treatment and Mortality in Men with Low Testosterone LevelsThe Journal of Clinical Endocrinology & Metabolism, 97(6), pp.2050-2058. 
 
Laughlin, G., Barrett-Connor, E. and Bergstrom, J. (2008). Low Serum Testosterone and Mortality in Older Men. The Journal of Clinical Endocrinology & Metabolism, 93(1), pp.68-75.
 
Khaw, K., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A. and Day, N. (2007). Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation,116(23), pp.2694-2701.
 
 
 
Cancer
 
Roddam, A., Allen, N., Appleby, P., Key, T. (2008). Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. Journal of the National Cancer Institute,100(3), pp.170-183.
 
 

DHEA
 

Villareal, D. and Holloszy, J. (2004). Effect of DHEA on Abdominal Fat and Insulin Action in Elderly Women and MenJAMA, 292(18), p.2243.
 
Oberbeck, R., Dahlweid, M., Koch, R., van Griensven, M., Emmendörfer, A., Tscherne, H. and Pape, H. (2001). Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Critical Care Medicine, 29(2), pp.380-384.
 
Wolkowitz, O., Reus, V., Keebler, A., Nelson, N. and Friedland,, M. (1999). Double-Blind Treatment of Major Depression with Dehydroepiandrosterone. The American Journal of Psychiatry, 156(4), pp.646-649. 
 
 
 
 
 
 

  
 
HOME    ABOUT BELMAR    PATIENTS    CLINICIANS     CONTACT BELMAR   PRIVACY POLICY
Belmar Pharmacy  800.525.9473  I  303.763.5533  I  12860 W. Cedar Drive, Suite 210  I  Lakewood, Colorado 80228